Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

The conversation is about analyzing receded temple closeups for signs of fibrosis, scarring, or androgenetic alopecia (AGA). Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned in the conversation.

The conversation discusses the difficulty of applying tretinoin 0.025% cream on the scalp and considers switching to a gel for easier application. It also mentions that a liquid solution, ideally combined with minoxidil, may be more effective for hair treatment.

The conversation discusses using microneedling with copper peptides, specifically GHK-Cu, for hair loss treatment. Some users combine it with minoxidil and topical finasteride, applying peptides either topically or through injection.

The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.

The conversation is about the effectiveness of peptides for hair loss and the user considering using GHK-Cu, CJC-1295, and BPC-157 for treatment.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

The conversation discusses the lack of experiments combining verteporfin and microneedling for hair loss treatment. The user expresses interest in participating in a group buy to try this method.

The user applied minoxidil and finasteride topically for hair regrowth, experiencing significant results but stopped finasteride due to side effects. They later added stevia to minoxidil, noticing potential improvement in hair density, particularly at the front.

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

The conversation discusses using minoxidil with microneedling and considering tretinoin to enhance hair growth, especially for those who are weak responders to minoxidil. It also explores the potential of using tazarotene, a stronger retinoid, to boost minoxidil's effectiveness and addresses purchasing tretinoin from Germany.

The user has been using Minoxidil and finasteride for two years, which stopped their hair loss but did not regrow hair. They are inquiring if adding microneedling or tretinoin has provided benefits to others in similar situations.

Theaflavin, a black tea extract, may inhibit DHT and androgen receptor activity, but its effectiveness for hair loss is debated. Users report no significant improvement with theaflavin, while some find beta sitosterol helpful.

A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.

The user reported significant hair regrowth after one month using Cécred edge drops, microneedling, and finasteride, despite skepticism from others. They had previously tried minoxidil, finasteride, PRP, and other treatments with limited success.

The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.

Using 0.025% tretinoin may enhance minoxidil's effects for hair loss. Users suggest starting with 0.025% and gradually increasing the concentration, and discuss combining treatments like microneedling.

Tretinoin may enhance minoxidil's effectiveness for those not responding to minoxidil alone, but it could reduce efficacy for some who are already responding to minoxidil. Tretinoin requires careful use, including skin moisturizing and sun protection due to increased sensitivity.

The conversation is about finding a place to buy 0.025% topical finasteride in liposomal gel form in Europe. The user previously mixed their own with stemoxydine but stopped due to an oily scalp.

The conversation is about a 21-year-old using finasteride, dermarolling, ketoconazole shampoo, hair growth serums, and exosome therapy to treat early-stage thinning on the crown. They are questioning if these treatments are sufficient to improve hair thickness.

The conversation discusses the effectiveness of using finasteride alone versus combining it with minoxidil, ketoconazole, and microneedling for hair loss treatment. It also touches on the affordability and accessibility of hair transplants, with differing opinions on the financial feasibility of such procedures.

The conversation discusses using scalp massage, balms like Ethera and L'Occitane, and dietary changes such as rosemary tea and tofu to address hair loss. The user is also considering high-intensity interval training and slow breathing to improve hair regrowth.

Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.

A user shared their experience with hair loss treatments, including I-PRF injections, mesotherapy, and a topical solution containing Minoxidil and Finasteride. After experiencing side effects, they decided to stop the medicinal treatments and focus on natural alternatives like I-PRF, microneedling, and essential oils.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.